window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Development

  • CDMOs & Manufacturing,Drug Development,Market Access & Commercialization,Partnerships & Funding,Technology and platforms

    Sphere Bio enters China market with Redbert Biotechnology distribution deal

    Sphere Bio has signed an exclusive distribution agreement with Redbert [...]

    June 27, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Drug Development,Technology and platforms

    AI can’t thrive in chaos: New survey finds labs still struggling with basics

    A new industry survey has revealed that while life sciences [...]

    June 27, 2025
  • Cell & Gene Therapy,Clinical Trials,Drug Development,Oncology,Technology and platforms

    Galapagos CAR-T therapy shows strong results in relapsed indolent NHL

    Galapagos has announced promising results from Cohort 3 of its [...]

    June 27, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Drug Development,Oncology,Precision medicine,Technology and platforms

    Galapagos taps CELLforCURE by SEQENS to manufacture CAR-T therapy in France

    CELLforCURE by SEQENS has partnered with Galapagos to manufacture GLPG5101, [...]

    June 27, 2025
  • CDMOs & Manufacturing,Drug Development,Oncology,Technology and platforms

    Orano Med invests $5M to expand US radiopharma capabilities

    Orano Med has expanded its US research and development center [...]

    June 27, 2025
  • CDMOs & Manufacturing,Cell & Gene Therapy,Drug Development,Oncology,Partnerships & Funding,Technology and platforms

    Mabion manufactures first batch of NovalGen’s bispecific T-cell engager for clinical trials

    Poland-based CDMO Mabion has completed the first GMP-compliant batch of [...]

    June 27, 2025
  • Artificial Intelligence,Drug Development,Patient Centricity,Technology and platforms

    Prenuvo research links alcohol and exercise to early brain and organ changes in asymptomatic adults

    Two new studies presented at the 2025 ISMRM Annual Meeting [...]

    June 27, 2025
  • Drug Development,Market Access & Commercialization,Partnerships & Funding,Patient Centricity

    Could a psychedelic transform depression care? Cybin CEO on scaling CYB003 with Osmind deal

    Cybin’s lead psychedelic-based candidate CYB003, designed as an adjunctive treatment [...]

    June 25, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development,Rare Diseases

    Game-changing £7.5M prize launches to unlock AI drug targets for ALS

    20 global teams will receive early-stage funding and access to [...]

    June 25, 2025
  • Clinical Trials,Drug Delivery & Formulation,Drug Development

    Oral hope for diabetic retinopathy: Breye completes positive Phase 1b trial of danegaptide

    Breye Therapeutics has announced the successful completion of its Phase [...]

    June 24, 2025
Previous192021Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Ribbon CEO calls for faster adoption of AI and DNA synthesis to accelerate drug development
    Categories: Biotech, Digital Health, Research & Development
  • FDA signals continued access for desiccated thyroid extract products as manufacturers move toward biologics pathway
    Categories: Regulatory Affairs, Research & Development
  • Tozorakimab meets primary endpoint in two Phase 3 COPD trials, showing reduction in exacerbations
    Categories: Clinical Trials, Research & Development, Respiratory
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top